The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
 
Matthew H. Kulke
Consulting or Advisory Role - Ipsen; Novartis
 
Donna Niedzwiecki
No Relationships to Disclose
 
Nathan R. Foster
No Relationships to Disclose
 
Briant Fruth
No Relationships to Disclose
 
Pamela L. Kunz
Stock and Other Ownership Interests - Guardant Health
Consulting or Advisory Role - Guardant Health; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications; Genentech/Roche; Lexicon; Merck; Merrimack; Novartis; Pharm-Olam
 
Hagen F. Kennecke
No Relationships to Disclose
 
Edward M. Wolin
No Relationships to Disclose
 
Alan P. Venook
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Onyx (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Halozyme; Merck Serono; Roche